Publications
17
Citations
12
Est. group size
—
Recurring co-author estimate
Active years
25
Publishing since 2002
Dr. O'Malley's work focuses on clinical trials for treating ovarian and endometrial cancers, particularly evaluating targeted drugs called PARP inhibitors (which block a DNA-repair enzyme, making them especially effective against tumors with certain genetic mutations like BRCA1/BRCA2) and immune-based therapies. This research involves large multi-site clinical studies testing new drug combinations and identifying which patients are most likely to benefit based on their tumor's genetic profile.
Publication output has been irregular over the past decade, with a cluster of activity in 2019-2021, a multi-year gap with no listed publications, and a resurgence expected in 2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract CT075: Lack of CTPS2 expression exposes synthetic lethal vulnerability to selective CTPS1 inhibition: A phase 1 dose escalation study of dencatistat (STP938) with safety expansion in biomarker selected cohorts
Cancer Research · 2026
- Exploratory analysis of ribociclib plus letrozole in recurrent low-grade serous ovarian carcinoma: Impact of prior therapy, chemotherapy exposure, and age (GOG-3026)
Gynecologic Oncology · 2026
- 272 Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study
International Journal of Gynecological Cancer · 2021
- 3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations
International Journal of Gynecological Cancer · 2020
- Evaluation of an individualized starting dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study
Geburtshilfe und Frauenheilkunde · 2020
- Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age
International Journal of Gynecological Cancer · 2019
- P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC)
International Journal of Gynecological Cancer · 2019
- 2 Exploratory analysis of postprogression and patient-centered outcomes in ariel3: a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma
International Journal of Gynecological Cancer · 2019
- Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3
International Journal of Gynecological Cancer · 2019
- BRCA1 and RAD51C Promoter Hypermethylation Confer Sensitivity to PARP Inhibitors in Patients with Platinum Sensitive Ovarian Carcinoma
UCL Discovery (University College London) · 2017
- Identification of germline and somatic alterations in homologous recombination pathway genes in high grade ovarian carcinomas and response to the PARP inhibitor rucaparib in ARIEL2
2016
- International Journal of Gynecological Cancer×6
- Cancer Research×2
- Gynecologic Oncology×2
- UCL Discovery (University College London)×1
- Geburtshilfe und Frauenheilkunde×1
- Zemin Wang
Medicine · Indiana University
- David M. O’Malley
Medicine · The Ohio State University
- John L. Hays
Medicine · The Ohio State University
- Larry J. Copeland
Medicine · The Ohio State University
- Stephanie V. Blank
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile